Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Janssen, Eisai, Apexian, Innovus And More

Executive Summary

Johnson & Johnson maintains hectic deal-making pace via RA tie-up with Monash and "diabesity" collaboration with UC San Diego.

You may also be interested in...



Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio

Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.

OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.

OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule

Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC099109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel